Hydroxylation at C-3′ of doxorubicin alters the selected phenotype of cellular drug resistance
- 17 August 1995
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 5 (16), 1807-1812
- https://doi.org/10.1016/0960-894x(95)00300-i
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Hydroxyrubicin, a deaminated derivative of doxorubicin, inhibits mammalian DNA topoisomerase II and partially circumvents multidrug resistanceInternational Journal of Cancer, 1994
- Cellular pharmacology of the partially non-cross-resistant anthracycline annamycin entrapped in liposomes in KB and KB-V1 cellsCancer Chemotherapy and Pharmacology, 1994
- Design and tumor targeting of anthracyclines able to overcome multidrug resistance: A double-advantage approachPharmacology & Therapeutics, 1993
- The nitrogen of the acetamido group of colchicine modulates P-glycoprotein-mediated multidrug resistanceBiochemistry, 1993
- Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicityAnti-Cancer Drugs, 1993
- Organ distribution and tumor uptake of annamycin, a new anthracycline derivative with high affinity for lipid membranes, entrapped in multilamellar vesiclesCancer Chemotherapy and Pharmacology, 1993
- Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell LineScience, 1992
- Relevance of the chemical charge of rhodamine dyes to multiple drug resistanceBiochemical Pharmacology, 1989
- Multidrug Resistance1JNCI Journal of the National Cancer Institute, 1988
- Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assaysJournal of Immunological Methods, 1983